Medidata NEXT NYC 2018 Abstract Submission
Author Contact Information
suggested format: Position, Department
example: VP, Biometrics
JPEG, 4” wide, 300 dpi
Professional bios must be between 100-300 words and will be published on the event website
Study Planning I - Reimagining Study Design
Study Planning II - Site Initiation & Patient Identification
Implementing Quality & Efficient Monitoring Practices
Process Optimization for Trial Management
Data Analytics to drive transformation across clinical research
Core Study Execution
RWD in Clinical Development or commercial
Proposed Session Format
If you have an idea of how you would like to present your abstract, please select from the options below
Debate (ex: moderator and max of 2 speakers for an interactive, lively discussion, putting forth opposing views on the session topic)
How-To Session (ex: tutorials for the novice or expert in biotech with 1 – 2 speakers. Addresses a specific topic or issue and provides practical lessons learned
Interactive Panel (ex: max of 3 speakers & 1 moderator to present a case study from multiple perspectives with Q&A from audience)
Interview (ex: one presenter, one moderator. Audience Q&A optional)
Abstract titles must be less than 10 words and will be published on the event website
Abstract Summary must be between 300-400 words maximum and will be published on the event website.
Speaker Release Acknowlegement
By clicking the boxes below, you acknowledge that you have read and agreed to Medidata's terms & conditions related to your participation in Medidata NEXT and your abstract submission.
I hereby grant Medidata Solutions, Inc. (together with its subsidiaries and affiliates, “Medidata”) permission to use the presentation I will provide at my NEXT session, which includes any information contained therein (e.g., name, biographical information, likeness, image, picture, voice, quotes, the abstract, all or a portion of interviews or video recordings from the session) or any customer testimonials whether written or recorded by video (collectively, "Speaker Content") in its promotional materials, public relations efforts, and on social media during and after the event (“Medidata Promotional Materials”). This includes the worldwide right to copy, translate, broadcast, transmit, distribute, exhibit, perform, publish and display the presentation as incorporated into the Medidata Promotional Materials.
I recognize that members of the press will attend the Medidata event and may be present in the session in which I am participating. I hereby grant my permission for members of the press to attend the session in which I am participating, understanding that information conveyed and materials presented are public record and may be reported via various media outlets.
Medidata is under no obligation to make use of or to provide compensation for any of the rights or permissions granted. Medidata shall be the exclusive owner of all right, title, and interest, including copyright, in the Medidata Promotional Materials.
This Permission may be terminated at any time with thirty (30) days prior written notice to Medidata, provided that such termination will not affect any action Medidata took in reliance on this Permission before termination. Upon termination, Medidata shall refrain from further use of the Speaker Content; provided, however, Medidata may continue to use the Speaker Content in Medidata Promotional Materials where such Medidata Promotional Materials have been placed in advertising media prior to notice of termination.
Speaker Passes to NEXT
Accepted abstracts will offer one free ticket to NEXT Global. Any additional presenters included in your session will be required to purchase a ticket at the current listed price
If you have questions or need help submitting your abstract, email us at email@example.com.
If you cannot agree to our speaking terms & conditions as listed above, and you are still interested in presenting at NEXT, please contact us at firstname.lastname@example.org and we will be in touch
Send me a copy of my responses
Your submission is being processed. Please do not close this browser window until complete.